Qinjian Zhao, Ph.D. 赵勤俭
Professor in Biochemistry and Vaccinology 教授 博导
Dr. Qinjian Zhao got his undergraduate and graduate training in pharmaceutical sciences in Peking University (1981 – 1989). Then he moved on to pursue a Ph.D. degree in Biochemistry in The Catholic University of America, Washington, DC (1989-1993). Subsequently, he did post-doctoral training in School of Medicine, Johns Hopkins University (1993-1997), focusing on protein structure and enzyme function. In 1997, Qinjian joined Merck Research Lab, Bioprocess R&D, working on the analytical and structural aspects of recombinant protein based vaccines, such as Recombivax HB and HPV vaccine/Gardasil. In vitro relative potency assays and developing and characterizing key immunochemical reagents are the main area of expertise – in support of vaccine development. After ~14 years’ work at Merck (1997-2011), Dr. Zhao joined Xiamen University in 2011, as part of the state “Thousand Talent Program”, working on diagnostics and vaccine/biologics development. Dr. Qinjian Zhao co-authored over 50 peer reviewed papers and 4 book chapters.
The main research area is in the field of vaccine research and development with emphasis on the fundamental understanding of structure-activity relationship of vaccines and biopharmaceuticals and on the establishment of the quality control system for vaccine production and on the facilitation of the CMC (chemistry, manufacturing, and controls) section writing in INDs, NDAs and BLAs. At Merck & Co., he played key roles in the establishment and implementation of critical in vitro relative potency assays for Hepatitis A vaccine (VAQTA®), Hepatitis B vaccine (RECOMBIVAX HB®), HPV vaccine (Gardasil®), second generation HPV vaccine and Pneumo conjugate vaccines. In Xiamen University, his main focus is to understand the mode of action of vaccine or therapeutic protein (TP) candidates and set up quality control system for vaccines (such as Hep E vaccine, Hecolin®) and biologics being developed at NIDVD to track the key product attributes to facilitate process monitoring & optimization and to assure vaccine and TP safety and efficacy.
主要研究方向为疫苗开发，构效关系确立，佐剂及抗原-佐剂间的相互作用分析，疫苗质控体系的建立等研发及产业化的关键领域。在美国默克公司期间领导一个核心团队负责所有产品的关键生化免疫分析。利用多种生化、物化及免疫分析手段开创疫苗和治疗性蛋白的等效性评价的新思路，并应用于多种产品的开发和改进，保证产品的工艺优化和生产的重现性与稳定性，建立的关键体外效力测定方法已用于HPV疫苗，甲肝疫苗和乙肝疫苗等产品的常规放行及稳定性测定。在疫苗和生物药物的研发中， 研究工作将着重于疫苗开发，构效关系确立，佐剂及抗原-佐剂间的相互作用分析，疫苗质控体系， 尤其是体外效力测定方法的建立等研发及产业化的关键领域。
1. Wei M, Zhang X, Yu H, Tang ZM, Wang K, Li Z, Zheng Z, Li S, Zhang J, Xia N, QinjianZhao*. Bacteria expressed hepatitis E virus capsid proteins maintain virion-like epitopes. Vaccine 2014.doi: 10.1016/j.vaccine.2014.02.025
2. Yibin Zhu TZ, Jinghua Zhao, Zusen Weng, Quan Yuan,Shaowei Li, Jun Zhang, Ningshao Xia*, QinjianZhao*. Towards the development of monoclonal antibody-based assays to probe virion-like epitopes in hepatitis B vaccine antigen. Human Vaccine and Immunotherapeutics 2014.doi:10.4161/hv.27753
3. Tingdong Li HL, Yue Zhang, Min Li, Daning Wang, Yaojian Che, Yinbin Zhu, Shaowei Li, Jun Zhang, Ningshao Xia, Shengxiang Ge*, QinjianZhao*. Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles. Vaccine2014 Apr 7;32(17):1921-31
4. QinjianZhao , Potter CS, Carragher B, Lander G, Sworen J, Towne V, Abraham D, Duncan P, Washabaugh MW, Sitrin RD. Characterization of virus-like particles in GARDASIL(R) by cryo transmission electron microscopy. Human vaccines & immunotherapeutics2014, 10(3): 0--1. PMID:24299977.
5.QinjianZhao, Li S, Yu H, Xia N, Modis Y. Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends in biotechnology 2013; 31:654-63.
6. QinjianZhao, Zhang J, Wu T, Li SW, Ng MH, Xia NS, Shih JW. Antigenic determinants of hepatitis E virus and vaccine-induced immunogenicity and efficacy. Journal of gastroenterology 2013; 48:159-68.
7. Wu T, Li SW, Zhang J, Ng MH, Xia NS, QinjianZhao*. Hepatitis E vaccine development: a 14 year odyssey. Human vaccines & immunotherapeutics 2012; 8:823-7.
8. Mulder AM, Carragher B, Towne V, Meng Y, Wang Y, Dieter L, Potter CS, Washabaugh MW, Sitrin RD, QinjianZhao*. Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine. PloS one 2012; 7:e33235.
9.QinjianZhao*, Modis Y, High K, Towne V, Meng Y, Wang Y, Alexandroff J, Brown M, Carragher B, Potter CS, et al. Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity. Virology journal 2012; 9:52.
10. QinjianZhao*, Allen MJ, Wang Y, Wang B, Wang N, Shi L, Sitrin RD. Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles. Nanomedicine: nanotechnology, biology, and medicine 2012; 8:1182-9.
11. QinjianZhao*, Wang Y, Abraham D, Towne V, Kennedy R, Sitrin RD. Real time monitoring of antigenicity development of HBsAg virus-like particles (VLPs) during heat- and redox-treatment. Biochemical and biophysical research communications 2011; 408:447-53.
12. QinjianZhao*, Towne V, Brown M, Wang Y, Abraham D, Oswald CB, Gimenez JA, Washabaugh MW, Kennedy R, Sitrin RD. In-depth process understanding of RECOMBIVAX HB(R) maturation and potential epitope improvements with redox treatment: multifaceted biochemical and immunochemical characterization. Vaccine 2011; 29:7936-41.
13. Towne V, Oswald CB, Mogg R, Antonello J, Will M, Gimenez J, Washabaugh M, Sitrin R, QinjianZhao. Measurement and decomposition kinetics of residual hydrogen peroxide in the presence of commonly used excipients and preservatives. Journal of pharmaceutical sciences 2009; 98:3987-96.
14. QinjianZhao*, Wang Y, Freed D, Fu TM, Gimenez JA, Sitrin RD, Washabaugh MW. Maturation of recombinant hepatitis B virus surface antigen particles. Human vaccines 2006; 2:174-80.
15. QinjianZhao, Yang XL, Holtzclaw WD, Talalay P. Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H:quinone reductase (DT-diaphorase). Proceedings of the National Academy of Sciences of the United States of America 1997; 94:1669-74.